Dr. Goldberg on Precision Medicine in Hematologic Malignancies

Stuart L. Goldberg, MD
Published: Thursday, Mar 01, 2018



Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.

The goal of precision medicine is to give the right patient the right treatment, explains Goldberg. If the patient receives the right therapy, it will make their quality and longevity of life better, and no money will be wasted, Goldberg adds.

It has been estimated that one-third of medicine is wasted, says Goldberg. If physicians use precision medicine properly, their patients will benefit, see the true value of the drug, and will not receive lines of ineffective therapies.
 


Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.

The goal of precision medicine is to give the right patient the right treatment, explains Goldberg. If the patient receives the right therapy, it will make their quality and longevity of life better, and no money will be wasted, Goldberg adds.

It has been estimated that one-third of medicine is wasted, says Goldberg. If physicians use precision medicine properly, their patients will benefit, see the true value of the drug, and will not receive lines of ineffective therapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Publication Bottom Border
Border Publication
x